Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, A/H7N9 influenza viruses underwent evolutionary changes. In this study, we examined the antigenic properties of influenza neuraminidase (NA) of A/H7N9 viruses as part of a live influenza vaccine (LAIV). It was shown that neuraminidase inhibiting (NI) antibodies obtained after A/Anhui/1/2013(H7N9)-based LAIV vaccination did not inhibit A/Hong Kong/125/2017(H7N9) NA and vice versa. The A/Hong Kong/125/2017(H7N9)-based LAIV elicited higher levels of NI antibodies compared to the A/Anhui/1/2013(H7N9)-based LAIV after two doses. Thelow degree of coincidence of the antibody response to hemagglutinin (HA) and NA after LAIV vaccination allows us to consider an enzyme-linked lectin assay (ELLA) as an additional measure for assessing the immunogenicity of influenza vaccines. In mice, N9-reactive monoclonal antibodies (mABs) for the A/environment/Shanghai/RL01/2013(H7N9) influenza virus partially protected against lung infection from the A/Guangdong/17SF003/2016 IDCDC-RG56N(H7N9) virus, thus showing the cross-protective properties of monoclonal antibodies against the drift variant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503534 | PMC |
| http://dx.doi.org/10.3390/ph15091127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.
Vaccine
January 2025
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Introduction: While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.
Methods: A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
Vaccine
January 2025
Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Article Synopsis
- Pandemic influenza vaccine development emphasizes the importance of hemagglutinin (HA) and neuraminidase (NA) antibodies for effective immune responses.
- Clinical trials show that NA inhibition antibody responses increase with higher doses and extended intervals between vaccine doses, indicating a potential strategy for enhancing immunity.
- The study indicates that while neuraminidase responses can be improved for better pandemic preparedness, the antibody responses to the HA stalk were minimal and not long-lasting.
A Closer Look at the Avian Influenza Virus H7N9: A Calm before the Storm?
J Med Virol
November 2024
Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
The avian influenza A (H7N9) virus, which circulates in wild birds and poultry, has been a major concern for public health since it was first discovered in China in 2013 due to its demonstrated ability to infect humans, causing severe respiratory illness with high mortality rates. According to the World Health Organization (WHO), a total of 1568 human infections with 616 fatal cases caused by novel H7N9 viruses have been reported in China from early 2013 to January 2024. This manuscript provides a comprehensive review of the virology, evolutionary patterns, and pandemic potential of H7N9.
View Article and Find Full Text PDFPandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA).
Lancet Microbe
October 2024
Global Influenza Programme, Epidemic and Pandemic Preparedness and Prevention, WHO Emergency Programme, World Health Organization, Geneva, Switzerland. Electronic address:
A systematic risk assessment approach is essential for evaluating the relative risk of influenza A viruses (IAVs) with pandemic potential. To achieve this, the Tool for Influenza Pandemic Risk Assessment (TIPRA) was developed under the Global Influenza Programme of WHO. Since its release in 2016 and update in 2020, TIPRA has been used to assess the pandemic risk of 11 zoonotic IAVs across ten evaluation rounds.
View Article and Find Full Text PDFClinical Management of Hospitalized Patients With High-Consequence Infectious Diseases in England.
Health Secur
September 2024
Alejandra Alonso, MPH, is a Consultant in Paediatric Infectious Diseases, Department of Infection, Evelina London Children's Hospital; Jonathan Cohen, PhD, is a Consultant in Paediatric Immunology and Infectious Diseases, Department of Paediatric Immunology and Infectious Diseases, Evelina London Children's Hospital; Chris Meadows, FRCP, is a Consultant in Intensive Care Medicine and ECMO, Department of Critical Care, St Thomas' Hospital; and Geraldine O'Hara, PhD, is a Consultant in Infectious Diseases, Department of Infectious Diseases, St Thomas' Hospital; all with Guy's and St Thomas' NHS Foundation Trust, London. Jonathan Cohen is also a Consultant, Department of Women and Children's Health, and Chris Meadows is also an Honorary Senior Lecturer, Faculty of Life Sciences and Medicine; both at St Thomas Hospital, Kings College London, London. Joby Cole, PhD, is a Consultant in Infectious Diseases and Acute Medicine, and Anne J. Tunbridge, FRCP, is a Consultant in Infectious Diseases; both in the Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield. Marieke Emonts, PhD, and Stephen Owens, PhD, are Consultants in Paediatric Infectious Diseases, Department of Paediatric Immunology and Infectious Diseases, Great North Children's Hospital; Brendan A. I. Payne, PhD, is a Consultant in Infectious Diseases and Virology, and Matthias L. Schmid, MD, is a Consultant in Infectious Diseases, Department of Infection and Tropical Medicine, Royal Victoria Infirmary; all with the Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne. Marieke Emonts is also an Honorary Professor, Paediatric Infectious Diseases, and Brendan A. I. Payne is also an Honorary Clinical Senior Lecturer; both at the Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne. Natasha Karunaharan, MRCPath, is a Consultant in Infectious Diseases and Microbiology, and Jake Dunning, PhD, is a Consultant in Infectious Diseases; both in the Department of Infectious Diseases, Royal Free Hospital, Royal Free London NHS Foundation Trust, London. Jake Dunning is also a Senior Research Fellow, Pandemic Sciences Institute, University of Oxford, Oxford. David Porter, PhD, and Andrew Riordan, FRCPCH, are Consultants in Paediatric Infectious Diseases and Immunology, Department of Paediatric Infectious Diseases and Immunology, Alder Hey Children's Hospital, Alder Hey Children's NHS Foundation Trust, Liverpool. Libuse Ratcliffe, FRCP, is a Consultant in Infectious Diseases, and Mike Beadsworth, MD, is a Consultant in Infectious Diseases and Tropical Medicine; both in the Tropical and Infectious Diseases Unit, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool. Ruchi Sinha, MRCPCH, is a Consultant Paediatric Intensivist, Children's Intensive Care, and Elizabeth Whittaker, PhD, is a Consultant in Paediatric Infectious Disease and Immunology, Children's Infectious Diseases; both at St Mary's Hospital, Imperial College Healthcare NHS Trust, London. Elizabeth Whittaker is also an Honorary Senior Clinical Lecturer, Section of Paediatric Infectious Diseases, Imperial College, London.
Infectious disease physicians in England have been diagnosing and managing occasional cases of viral hemorrhagic fever since 1971, including the United Kingdom's first case of Ebola virus disease in 1976. Specialist isolation facilities to provide safe and effective care have been present since that time. Following the emergence of Middle East respiratory syndrome (MERS) in 2012, and the avian influenza A (H7N9) outbreak in 2013, and the 2014-2016 Ebola virus disease outbreak in West Africa, clinical and public health preparedness and response pathways in England have been strengthened for these types of diseases, now called high-consequence infectious diseases (HCIDs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!